Skip to main content Skip to search
Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy
Short Title: Cancer
Format: Journal Article
Publication Date: Nov 30, 2017
Pages: 36 - 45
Sources ID: 32776
Notes: LR: 20180216; CI: (c) 2017; GR: K01 AT007559/AT/NCCIH NIH HHS/United States; GR: P30 CA016672/CA/NCI NIH HHS/United States; GR: R01 CA105023/CA/NCI NIH HHS/United States; JID: 0374236; 0 (Antineoplastic Agents); 0 (Taxoids); 15H5577CQD (docetaxel); 3Z8479ZZ5X (Epirubicin); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); U3P01618RT (Fluorouracil); NIHMS896104; OTO: NOTNLM; PMCR: 2019/01/01 00:00; 2016/11/14 00:00 [received]; 2017/05/23 00:00 [revised]; 2017/07/11 00:00 [accepted]; 2019/01/01 00:00 [pmc-release]; 2017/09/25 06:00 [pubmed]; 2017/12/27 06:00 [medline]; 2017/09/24 06:00 [entrez]; ppublish
Visibility: Public (group default)
Abstract: (Show)
BACKGROUND: The current randomized trial examined the effects of a Tibetan yoga program (TYP) versus a stretching program (STP) and usual care (UC) on sleep and fatigue in women with breast cancer who were undergoing chemotherapy. METHODS: Women with stage (American Joint Committee on Cancer (AJCC) TNM) I to III breast cancer who were undergoing chemotherapy were randomized to TYP (74 women), STP (68 women), or UC (85 women). Participants in the TYP and STP groups participated in 4 sessions during chemotherapy, followed by 3 booster sessions over the subsequent 6 months, and were encouraged to practice at home. Self-report measures of sleep disturbances (Pittsburgh Sleep Quality Index), fatigue (Brief Fatigue Inventory), and actigraphy were collected at baseline; 1 week after treatment; and at 3, 6, and 12 months. RESULTS: There were no group differences noted in total sleep disturbances or fatigue levels over time. However, patients in the TYP group reported fewer daily disturbances 1 week after treatment compared with those in the STP (difference, -0.43; 95% confidence interval [95% CI], -0.82 to -0.04 [P = .03]) and UC (difference, -0.41; 95% CI, -0.77 to -0.05 [P = .02]) groups. Group differences at the other time points were maintained for TYP versus STP. Actigraphy data revealed greater minutes awake after sleep onset for patients in the STP group 1 week after treatment versus those in the TYP (difference, 15.36; 95% CI, 7.25-23.48 [P = .0003]) and UC (difference, 14.48; 95% CI, 7.09-21.87 [P = .0002]) groups. Patients in the TYP group who practiced at least 2 times a week during follow-up reported better Pittsburgh Sleep Quality Index and actigraphy outcomes at 3 months and 6 months after treatment compared with those who did not and better outcomes compared with those in the UC group. CONCLUSIONS: Participating in TYP during chemotherapy resulted in modest short-term benefits in sleep quality, with long-term benefits emerging over time for those who practiced TYP at least 2 times a week. Cancer 2018;124:36-45. (c) 2017 American Cancer Society.